Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial.

chemotherapy-related toxicities nurse telephone monitoring intervention patient-reported outcome measures quality of life randomized multicenter trial

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 21 04 2022
accepted: 17 08 2022
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 4 10 2022
Statut: epublish

Résumé

Anticancer treatment-related toxicities can impact morbidity and mortality, hamper the administration of treatment, worsen the quality of life and increase the burden on the healthcare system. Therefore, their prompt identification is crucial. NICSO (Italian Network for Supportive Care in Cancer) conducted a nationwide randomized trial to evaluate the role of a planned, weekly phone-based nurse monitoring intervention to prevent and treat chemotherapy, targeted therapy- and immunotherapy-related toxicities. Here, we report the results from the chemotherapy arm. This was a nationwide, randomized, open-label trial conducted among 29 Italian centers (NCT04726020) involving adult patients with breast, colon, or lung cancer and a life expectancy ≥6 months receiving adjuvant chemotherapy. Patients received either a weekly nurse monitoring phone call and an educational leaflet reporting practical advice about prevention and treatment of toxicities (experimental group) or the educational leaflet only (control group). The addition of a nurse monitoring intervention may help reduce time spent with severe toxicities (grade ≥3), particularly those less frequently reported in clinical practice, such as fatigue. When considering grade 1-2 AEs, times with mild/moderate diarrhea, mucositis, fatigue and pain were shorter in the experimental arm. Time spent without AEs was significantly longer in the experimental arms for all the toxicities. The requirement for special medical attention was comparable between groups. This study suggests the need for implementing a better system of toxicity assessment and management for patients treated with adjuvant chemotherapy to promote effective preventive and/or therapeutic intervention against these events.

Identifiants

pubmed: 36185306
doi: 10.3389/fonc.2022.925366
pmc: PMC9520968
doi:

Types de publication

Journal Article

Langues

eng

Pagination

925366

Informations de copyright

Copyright © 2022 Antonuzzo, Ripamonti, Roila, Sbrana, Galli, Miccinesi, Sammarco, Berruti, Coletta, Velutti, Fabi, Corsi, Mariani, Di Pede, Spinelli, Santini, Zustovich, Gunnellini, Rossi, Giordano, Di Maio, Numico and Bossi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Support Care Cancer. 2020 Aug;28(8):3897-3904
pubmed: 31848704
Support Care Cancer. 2018 Feb;26(2):557-564
pubmed: 28871358
Ann Oncol. 2015 Sep;26(9):1846-1858
pubmed: 25888610
BMJ. 2021 Jul 21;374:n1647
pubmed: 34289996
J Clin Oncol. 2009 Dec 20;27(36):6191-8
pubmed: 19917849
J Public Health Med. 2001 Sep;23(3):227-34
pubmed: 11585196
Support Care Cancer. 2009 Apr;17(4):437-44
pubmed: 18953579
Cochrane Database Syst Rev. 2020 Jun 2;6:CD007568
pubmed: 32483832
Crit Care. 2017 Apr 14;21(1):89
pubmed: 28407743
Biomed Res Int. 2016;2016:3989286
pubmed: 26981530
J Clin Oncol. 2021 Jun 20;39(18):1983-1994
pubmed: 33822650
JAMA Oncol. 2018 Jan 01;4(1):105-117
pubmed: 28570732
Ann Oncol. 2020 Jun;31(6):713-723
pubmed: 32173483
JAMA Oncol. 2017 Aug 01;3(8):1043-1050
pubmed: 28208174
Support Care Cancer. 2019 Dec;27(12):4525-4534
pubmed: 30915567
Nat Rev Clin Oncol. 2016 May;13(5):319-25
pubmed: 26787278
Am Soc Clin Oncol Educ Book. 2018 May 23;38:13-19
pubmed: 30231401
Lancet Haematol. 2020 Jun;7(6):e490-e497
pubmed: 32470440
Lancet Oncol. 2016 May;17(5):663-70
pubmed: 27083333
Eur J Oncol Nurs. 2017 Feb;26:63-82
pubmed: 28069154
Ann Transl Med. 2016 Jul;4(14):272
pubmed: 27563659
J Clin Oncol. 2021 Mar 1;39(7):734-747
pubmed: 33417506
JCO Oncol Pract. 2021 Mar;17(3):e386-e396
pubmed: 32853122
Oncotarget. 2017 Sep 18;8(50):87598-87606
pubmed: 29152104
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Pain Pract. 2021 Apr;21(4):388-393
pubmed: 33200548
Support Care Cancer. 2019 Nov;27(11):4099-4106
pubmed: 30783815
J Cancer Surviv. 2021 Feb;15(1):163-177
pubmed: 32986232
J Patient Rep Outcomes. 2020 Oct 30;4(1):88
pubmed: 33125537
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
J Med Internet Res. 2019 Mar 28;21(3):e9958
pubmed: 30920373

Auteurs

Andrea Antonuzzo (A)

UO Oncologia Medica 1 SSN Polo Oncologico, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Carla Ida Ripamonti (CI)

Oncology-Supportive Care Unit, Department Medical Oncology & Haematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.

Fausto Roila (F)

SC Oncologia Medica, Azienda Ospedaliera Universitaria "S. Maria della Misericordia", Perugia, Italy.

Andrea Sbrana (A)

Servizio di Pneumo-Oncologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Luca Galli (L)

UO Oncologia Medica 1 SSN Polo Oncologico, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Guido Miccinesi (G)

Clinical Epidemiology Unit, Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Firenze, Italy.

Enrico Sammarco (E)

UO Oncologia Medica 1 SSN Polo Oncologico, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Alfredo Berruti (A)

SC Oncologia Medica, ASST Spedali Civili di Brescia, Brescia, Italy.

Deborah Coletta (D)

UOSD Oncologia, Policlinico Tor Vergata, Rome, Italy.

Laura Velutti (L)

Medical Oncology and Hematology Unit - IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy.

Alessandra Fabi (A)

Divisione Oncologia Medica A, IFO Istituto per la Ricerca dei Tumori Regina Elena, Rome, Italy.

Domenico Cristiano Corsi (DC)

Ospedale San Giovani Calibita Fatebenefratelli - Isola Tiberina, Rome, Italy.

Gabriella Mariani (G)

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Patricia Di Pede (P)

Oncology-Supportive Care Unit, Department Medical Oncology & Haematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.

Gian Paolo Spinelli (GP)

Unitá Operativa di Oncologia Universitaria della Casa della Salute di Aprilia, UOC Oncologia Universitaria, Aprilia, Italy.

Daniele Santini (D)

UOC Oncologia Medica, Campus Bio-Medico, Rome, Italy.

Fable Zustovich (F)

UOC Oncologia, AULSS 1 Dolomiti, Ospedale San Martino, Belluno, Italy.

Marco Gunnellini (M)

UO Oncologia, Ospedale di Gubbio - Gualdo Tadino, Gubbio, Italy.

Maura Rossi (M)

SC Oncologia, ASO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Monica Giordano (M)

Oncologia, Ospedale S. Anna, Como, Italy.

Massimo Di Maio (M)

Dipartimento di Oncologia, Università di Torino, AO Ospedale Mauriziano, Turin, Italy.

Gianmauro Numico (G)

Department of Medical Oncology, Santa Croce e Carle Hospital, Cuneo, Italy.

Paolo Bossi (P)

SC Oncologia Medica, ASST Spedali Civili di Brescia, Brescia, Italy.

Classifications MeSH